Advertisement

Topic - Allergan Plc

Related Stories

Illustration on the need for patent examiners by Alexander Hunter/The Washington Times

Patents need to be protected

By John Thorne

Drug companies ask Oklahoma judge to dismiss opioid lawsuit

Associated Press

This Aug. 8, 2016, photo provided by Allergan shows Brent Saunders. Saunders, CEO of Botox maker Allergan PLC, last September 2016, announced a new &quot;social contract&quot; under which the company would limit annual list price increases for its drugs to below 10 percent. After deducting the discounts insurers and other payers get off the higher list price, Allergan will receive net price increases of around 2 percent to 3 percent on its drugs, Saunders said. (Jeff Weiner/Allergan via AP)

Insider Q&A: Allergan CEO on impact of limiting price hikes

By LINDA A. JOHNSON - Associated Press

In this Nov. 23, 2015, file photo, traders James Matthews, left, and John Panin work at the post that handles Pfizer, on the floor of the New York Stock Exchange. Allergan and Pfizer called off Wednesday, April 6, 2016, a record $160 billion merger after the Treasury issued new rules to make "tax inversions" less lucrative. (AP Photo/Richard Drew, File)

Allergan, Pfizer call off proposed $160B merger

Associated Press

A woman passes Pfizer's world headquarters, Monday, Nov. 23, 2015, in New York. Pfizer and Allergan will join in a $160 billion deal to create the world's largest drugmaker. (AP Photo/Mark Lennihan)

Pfizer, Allergan combining in $160 billion deal

Associated Press